trastuzumab deruxtecan
AstraZeneca Optimistic About Phase III Camizestrant Data in 2025, Reports Strong Q4 Product Growth
Premium
If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.
HER2 Biomarker Evolving as Enhertu Shows Activity in Breast Cancers With Ultralow Expression
Premium
The new HER2-low category is exposing the limitations of IHC testing, challenging pathologists, and has oncologists revisiting patients' old test results.
AstraZeneca Reports Q3 Revenue Growth for Precision Cancer Drugs Amid Ongoing China Investigations
Premium
One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.
AstraZeneca Advancing Plan to Launch Biomarker-Driven Drugs as Alternative to Chemo in Breast Cancer
Premium
The drugmaker wants to establish Enhertu in HER2-ultralow breast cancer and even HER2-negative tumors but remains committed to precision medicine strategies.
AstraZeneca, Daiichi Sankyo's Enhertu BLA in HER2-Low, Ultralow Breast Cancer Gets FDA Priority Review
The FDA expects to issue a decision in the first quarter of 2025, and if the agency grants approval, it will expand the biomarker-eligible population for the drug.